424 Capital recently announced that it has completed a significant investment in VaLogic, a leading provider of GMP (Good Manufacturing Practice) and GLP (Good Laboratory Practice) compliance software and services based in Frederick, MD. This strategic deal by 424 Capital aims to expedite positive clinical outcomes by enabling pharmaceutical and biotechnology organizations to focus on the research, development, and production of cutting-edge therapeutics in a compliant and effective manner.
Launched in 2001 by CEO Bill Robertson, VaLogic offers a comprehensive range of software and compliance services to the life science and biotechnology market. And these services help organizations and facilities maintain GMP compliance and enact high standards while focusing on advancing life-saving therapeutics.
VaLogic provides advisory and facility design, full commissioning and qualification, cleanroom environmental monitoring, HEPA/cleanroom certifications, calibration, preventative maintenance, and a proprietary SaaS software called LogiPoint for continuous monitoring of critical facilities and equipment.
This partnership with 424 Capital is an important milestone in VaLogic’s business growth and expansion plans. It further supports progress in the biotechnology, life sciences, and pharmaceutical industries.
The partnership between VaLogic and 424 Capital is expected to have a major impact on early-stage life science and biotechnology companies, expediting research, product development, and production.
KEY QUOTES:
“This is a momentous occasion for VaLogic as we celebrate our long and successful journey and prepare for future growth. We are thrilled to announce our new business partnership, which will enable us to pursue our strategic goals, expand into new markets and attract new clients. It will also allow us to offer a wider range of services in our current and emerging areas of expertise. We take pride in our talented teams who will continue to deliver high-quality service to our clients. Additionally, we are excited about the increased career opportunities this partnership will bring for our employees. As we enter 2024 and beyond, this partnership presents a tremendous opportunity for us to achieve our vision of growth and excellence.”
— Bill Robertson, CEO of VaLogic
“424 Capital seeks to invest in important mission-driven companies, and VaLogic provides vital technology and services to clients in the life science and biotechnology sectors. We are excited to support the team in their ambition to scale their services and enable VaLogic’s customers to accelerate cures and therapies in many critical healthcare disciplines.”
— Brennan Mulcahey, Managing Partner at 424 Capital
